Could a Low-Protein diet boost immunotherapy for melanoma?
NCT ID NCT07586891
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a low branched-chain amino acid (BCAA) diet, when combined with an immunotherapy drug (anti-PD-1), is safe and effective for people with stage III melanoma. About 80 participants will receive either the special diet or a normal diet alongside the immunotherapy. The goal is to see if the diet helps the immune system fight the cancer better, with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
low branched-chain amino acid diet and anti-PD-1 monoclonal antibody
What this could lead to
If successful, this combination could improve how well immunotherapy works for stage III melanoma, potentially leading to better tumor shrinkage and longer survival.
What could go wrong
This is a small, early exploratory study with only 80 participants. The diet may not add benefit over standard immunotherapy, and side effects from the combination are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xijing Hospital, Air Force Medical University
RECRUITINGXi'an, China
Contact Phone: •••-•••-•••• Email: •••••@•••••